Myovant Sciences has made four key appointments to its managing team. Matthew Lang, J.D., has joined the company as general counsel and corporate secretary; Juan Camilo Arjona Ferreira, M.D., has joined as chief medical officer; Teresa Perney, Ph.D., has joined as senior VP of Regulatory Affairs and Quality Assurance; and Andria Langenberg, M.D., has joined as head of Drug Safety and Pharmacovigilance.

“I am very pleased with the caliber of our new corporate leaders and look forward to working closely with them,” says Lynn Seely, M.D., president and CEO of Myovant Sciences. “Each is an accomplished leader with decades of highly relevant experience and shares our commitment to delivering innovative therapies for women’s health and endocrine diseases.”

Lang was previously VP, Head of Global Litigation, Investigations, Employment Law and Information Governance at Gilead Sciences Inc. At Gilead, in addition to leading core functions within the legal department, Lang was a member of the company’s Corporate Operating Group, Global Legal Leadership Team, and Global Compliance Committee. Prior to Gilead, Lang was an attorney at Dechert LLP in New York City. He received his BA in classical studies from Queen’s University in Canada and his JD from the University of Pennsylvania Law School.

Dr. Arjona Ferreira was senior VP, Clinical Development at Shionogi Inc. At Shionogi, Dr. Arjona Ferreira was responsible for leading the company’s U.S. Clinical Development organization and he served on the company’s U.S. Senior Leadership Team and the Global Scientific Committee. Before joining Shionogi, Dr. Arjona Ferreira spent more than a decade at Merck & Co. where he was executive director of clinical research in Women’s Health. At Merck, he chaired the product development teams for all programs in contraception and women’s health. Dr. Arjona Ferreira earned his M.D. and completed his postgraduate specialist training in obstetrics and gynecology at Colegio Mayor del Rosario in Bogota, Colombia.

Dr. Perney had been medicine team leader for Xtandi and talazoparib at Pfizer Inc. Before joining Pfizer, Dr. Perney held positions of increasing responsibility within regulatory affairs at several pharmaceutical companies, including Medivation Inc., Hoffman-La Roche/Genentech Inc., and Schering-Plough Corp. She has global regulatory experience in multiple therapeutic areas including oncology, cardiovascular, metabolic diseases, immunology, and respiratory diseases. Dr. Perney received her BA in biology from Northwestern University and her Ph.D. in neurobiology from the University of Chicago.

Dr. Langenberg was VP of Drug Safety and Pharmacovigilance at Medivation Inc., where she had served as VP of Clinical Development. Dr. Langenberg has two decades of experience in drug development and has held positions of increasing responsibility within clinical development at Neosil Inc., Corgentech Inc., BioMarin Pharmaceutical Inc., and Chiron Corp. Dr. Langenberg is board certified in internal medicine and dermatology and completed her internship and residency at the University of California, San Francisco.

Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women’s health and endocrine diseases.